Integrated Clinical Study of Traditional Chinese and Western Medicine for Refractory Rheumatoid Arthritis

To evaluate the efficacy and safety of Kunxian Capsule combined with Methotrexate and Tofacitinib in the treatment of difficult-to-treat rheumatoid arthritis through a multicenter, randomized, double-blind, placebo-controlled clinical trial, and to identify the therapeutic advantages of integrated Chinese and Western medicine for optimizing the clinical strategy of D2T RA.

NCT Number	NCT07721142
Lead Sponsor	Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
Conditions	Rheumatoid Arthritis (RA)
Enrollment	300 participants
Start Date	2025-10-15
Primary Completion	2028-03-15 (estimated)
Study Completion	2028-03-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-22